A Study for the Treatment of Diabetic Peripheral Neuropathic Pain
Launched by ELI LILLY AND COMPANY · Oct 31, 2007
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with pain due to bilateral peripheral neuropathy induced by type 1 or 2 diabetes mellitus. The pain must have been present for at least 6 months and be evaluable in feet, legs, or hands.
- • Participants with hemoglobin A1c (HbA1c) less than or equal to 9.0 percent at Visit 1.
- • Participants in whom HbA1c had been measured 42-70 days before Visit 1 and subsequent HbA1c levels have been within +/- 1.0 percent of the level at Visit 1.
- • Participants with a mean of the 24-hour average pain severity scores (round off to a whole number) of 4 or higher, as calculated from the patient diary for 7 days immediately before Visit 2
- Exclusion Criteria:
- • Participants who have undergone renal transplant or who are currently on renal dialysis.
- • Participants who have a history requiring pharmacotherapy within the past year or current history of psychiatric disease, such as mania, bipolar disorder, depression, anxiety disorder, or eating disorder.
- • Participants with hypertension with poor control of blood pressure (systolic blood pressure greater than or equal to 180 millimeters of mercury (mmHg) or diastolic blood pressure greater than or equal to 110 mmHg
- • Participants with alanine transaminase (ALT) or aspartate transaminase (AST) greater than or equal to 100 Units per Liter (U/L) at Visit 1.
- • Participants unable to discontinue prohibited concomitant drugs or concomitant therapies after Visit 1.
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aichi, , Japan
Chiba, , Japan
Fukuoka, , Japan
Fukushima, , Japan
Gunma, , Japan
Kanagawa, , Japan
Niigata, , Japan
Osaka, , Japan
Saitama, , Japan
Tokyo, , Japan
Fukui, , Japan
Hokkaido, , Japan
Ibaraki, , Japan
Miyagi, , Japan
Shizuoka, , Japan
Tochigi, , Japan
Tokushima, , Japan
Toyama, , Japan
Aomori, , Japan
Hiroshima, , Japan
Hyogo, , Japan
Kagoshima, , Japan
Kyoto, , Japan
Oita, , Japan
Okayama, , Japan
Patients applied
Trial Officials
Call 1-877-CTLILLY(1-877-285-4559) OR 1-317-615-4559 Mon-Fri 9 AM-5 PM Eastern time (UTC/GMT-5 hours,EST)
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials